Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Director | November 13, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date November 13, 2019 · Filed November 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Signet Healthcare Partners Accredited Partnership III, LP | 106,052 |
Reported balance
After 2019-11-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-13 · Conversion · Acquired 59,940 · Balance 106,052 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2: Reflects 46,112 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Common StockSEC Table I · non-derivative | IndirectBy Signet Healthcare Partners QP Partnership III, LP | 505,281 |
Reported balance
After 2019-11-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-13 · Conversion · Acquired 285,580 · Balance 505,281 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3: Reflects 219,701 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). F4: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Signet Healthcare Partners Accredited Partnership III, LP | 0 |
Reported balance
After 2019-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-13 · Conversion · Disposed 1,479,951 · Balance 0 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Signet Healthcare Partners QP Partnership III, LP | 0 |
Reported balance
After 2019-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-13 · Conversion · Disposed 7,051,009 · Balance 0 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy Signet Healthcare Partners Accredited Partnership III, LP | 0 |
Reported balance
After 2019-11-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-13 · Conversion · Disposed 31,168 · Balance 0 F5: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy Signet Healthcare Partners Accredited Partnership III, LP | 31,168 |
Reported balance
After 2019-11-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-13 · Conversion · Acquired 31,168 · Balance 31,168 F5: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy Signet Healthcare Partners Accredited Partnership III, LP | 148,499 |
Reported balance
After 2019-11-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-13 · Conversion · Acquired 148,499 · Balance 148,499 F5: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy Signet Healthcare Partners QP Partnership III, LP | 0 |
Reported balance
After 2019-11-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-13 · Conversion · Disposed 148,499 · Balance 0 F5: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F2: Reflects 46,112 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F3: Reflects 219,701 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F4: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
F5: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 148,499 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 8 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners Accredited Partnership III, LP Disclosed balance after: 148,499 Underlying: Common Stock · 6,014 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 148,499 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 7 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners QP Partnership III, LP Disclosed balance after: 0 Underlying: Series B Preferred Stock · 148,499 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 31,168 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 6 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners Accredited Partnership III, LP Disclosed balance after: 31,168 Underlying: Common Stock · 1,262 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 31,168 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 5 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners Accredited Partnership III, LP Disclosed balance after: 0 Underlying: Series B Preferred Stock · 31,168 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 7,051,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 4 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners QP Partnership III, LP Disclosed balance after: 0 Underlying: Common Stock · 285,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 1,479,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · derivative · entry 3 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners Accredited Partnership III, LP Disclosed balance after: 0 Underlying: Common Stock · 59,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 285,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · nonDerivative · entry 2 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners QP Partnership III, LP Disclosed balance after: 505,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · balance_after: Reflects 219,701 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). F4 · balance_after: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 59,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000421 · edgar.xml · nonDerivative · entry 1 Friedman Ashley · CIK 0001790193 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Signet Healthcare Partners Accredited Partnership III, LP Disclosed balance after: 106,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 46,112 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.